Dupilumab treatment for severe chronic rhinosinusitis with nasal polyps: efficacy and impact on co-existing mild to moderate asthma

Aim: This study aims at assessing dupilumab’s response in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and its impact on concurrent mild to moderate asthma. Methods: The study involved severe, uncontrolled CRSwNP patients starting dupilumab treatment (300 mg/2 weeks) at the Allergy unit...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Niki Papapostolou, Michael Makris
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Open Exploration Publishing Inc. 2024-06-01
Edice:	Exploration of Asthma & Allergy
Témata:	asthma chronic rhinosinusitis with nasal polyps (crswnp) dupilumab biologic agent type 2 inflammation
On-line přístup:	https://www.explorationpub.com/uploads/Article/A100939/100939.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!